ClinicalTrials.gg
CompletedNCT03068312Updated Feb 26, 2020Results posted

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

A Phase 3 interventional study of Ivacaftor and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in Israel. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2020-02-26.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
60th of 84
38 · median 70
Started
2017
with 6 others
Phase 3
45 of 84
none open now
Registered
47th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 60th largest by enrollment, is one of 7 that started in 2017, is one of 45 in phase 3, and was the 47th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of ivacaftor treatment in subjects with CF 6 years of age and older who have a 3849 + 10KB C→T or D1152H CFTR mutation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CF based on protocol-specified clinical features and at least one of the following: increased sweat chloride level, identification of 2 CF causing mutations, or demonstration of abnormal nasal epithelial ion transport.
  • A 3849 + 10KB C→T or D1152H mutation on at least 1 CFTR allele.
  • ≥40% of predicted and ≤105% of predicted at screening.

Exclusion criteria

Exclusion Criteria:

  • A G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H mutation.
  • History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • Ongoing or prior participation in an drug study within 30 days before the Screening Visit.
  • Protocol-specified abnormal laboratory values at the Screening Visit
  • For subjects \<18 years of age at the Screening Visit, evidence of cataract/lens opacity determined to be by the ophthalmologist or optometrist during the ophthalmologic examination (OE) at the Screening Visit.
  • Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A, including consumption of certain herbal medications and certain fruit and fruit juices, within 14 days before Day 1.
  • Pregnant, breastfeeding, or planning to become pregnant during the study.
  • Sexually active subjects of must be willing to use appropriate .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Sequence 1: First Ivacaftor (IVA) Then Placebo

    Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.

    Drug: Ivacaftor · Drug: Placebo

  • Experimental
    Sequence 2: First Placebo Then IVA

    Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.

    Drug: Ivacaftor · Drug: Placebo

Interventions

  • IVA 150 mg tablet.

    Also known as: VX-770, IVA

  • DrugPlacebo

    Placebo matched to IVA tablet.

06

What researchers measure

Primary outcomes

  1. Change in Lung Clearance Index 2.5 (LCI2.5)

    LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

    Time frame: From baseline through 8 weeks

07

Results

Posted Jan 6, 2020

Participant flow

Participant flow — Overall Study
MilestoneSequence 1: First Ivacaftor (IVA) Then PlaceboSequence 2: First Placebo Then IVA
Started1919
Completed1919
Not completed00

Outcome measures

PrimaryChange in Lung Clearance Index 2.5 (LCI2.5)

LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

Time frame:
From baseline through 8 weeks
Reported as:
Least squares mean · lung clearance index
Change in Lung Clearance Index 2.5 (LCI2.5)
lung clearance indexPlaceboIvacaftor
Change in Lung Clearance Index 2.5 (LCI2.5)0.20 ± 0.19-0.46 ± 0.19
Statistical analysis
  • Placebo vs Ivacaftor · Least squares mean difference: -0.66 · 95% CI -1.10 to -0.21

Adverse events

Collected over From first dose of study drug up to safety follow-up visit (up to Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/38 (0%)2/38 (5.3%)19/38 (50%)
Ivacaftor0/38 (0%)1/38 (2.6%)12/38 (31.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboIvacaftor
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/381/38
PancreatitisGastrointestinal disorders1/380/38
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations1/380/38
Most frequent other events
Most frequent other events
EventPlaceboIvacaftor
Viral upper respiratory tract infectionInfections and infestations9/381/38
Upper respiratory tract infectionInfections and infestations6/383/38
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/385/38
HaemoptysisRespiratory, thoracic and mediastinal disorders2/383/38
HeadacheNervous system disorders2/381/38
PyrexiaGeneral disorders1/382/38
MalaiseGeneral disorders2/380/38
Aphthous ulcerGastrointestinal disorders2/380/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence 1: First IVA Then PlaceboSequence 2: First Placebo Then IVATotal
Mean32.6 ± 15.332.1 ± 15.632.3 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: First IVA Then PlaceboSequence 2: First Placebo Then IVATotal
Female101020
Male9918
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1: First IVA Then PlaceboSequence 2: First Placebo Then IVATotal
Hispanic or Latino000
Not Hispanic or Latino191938
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: First IVA Then PlaceboSequence 2: First Placebo Then IVATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White191938
More than one race000
Unknown or Not Reported000
Lung Clearance Index 2.5 (LCI2.5)
Lung Clearance Index 2.5 (LCI2.5)(lung clearance index)Sequence 1: First IVA Then PlaceboSequence 2: First Placebo Then IVATotal
Mean12.74 ± 4.0413.19 ± 5.4512.96 ± 4.74
08

Study locations

1 site
  • Hadassah Medical Organization
    Jerusalem, Israel
09

References and documents

Publications

  • Kerem E, Cohen-Cymberknoh M, Tsabari R, Wilschanski M, Reiter J, Shoseyov D, Gileles-Hillel A, Pugatsch T, Davies JC, Short C, Saunders C, DeSouza C, Sullivan JC, Doyle JR, Chandarana K, Kinnman N. Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C-->T or D1152H Residual Function Mutation. Ann Am Thorac Soc. 2021 Mar;18(3):433-441. doi: 10.1513/AnnalsATS.202006-659OC. PubMed 33095038 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Dec 2018, 17 months.

Results were first posted in Jan 2020, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 17 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2017
First posted
Mar 1, 2017
StartActual
Jul 18, 2017
Primary completionActual
Dec 18, 2018
CompletionActual
Dec 18, 2018
Results first posted
Jan 6, 2020
Last update
Feb 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03068312
Responsible party
Sponsor
First posted
Mar 1, 2017
Start date
Jul 18, 2017
Primary completion
Dec 18, 2018
Completion
Dec 18, 2018
Results posted
Jan 6, 2020
Last update
Feb 26, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion